Amgen, Inc. vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Amgen, Inc. trades at $412.77 (market cap $224.14B), while Direxion Daily TSLA Bull 2X Shares trades at $8.33. The key difference: Amgen, Inc. pays a 2.43% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Amgen, Inc. is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| AMGN | TSLL | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $417.20 | $23.03 |
52-Week Low | $271.18 | $6.74 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →